Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration,
Год журнала:
2024,
Номер
unknown, С. 1 - 4
Опубликована: Дек. 22, 2024
ALSUntangled
reviews
alternate
and
off-label
treatments
prompted
by
patient
interest.
Here,
we
review
psilocybin,
a
chemical
derived
from
mushrooms
belonging
in
the
category
of
drugs
known
as
psychedelics.
Psilocybin
has
plausible
mechanisms
for
slowing
ALS
progression
because
its
ability
to
cross
blood
brain
barrier
effect
neurogenesis
inflammation.
Currently,
there
are
no
pre-clinical
models,
case
reports,
or
trials
psilocybin
context
disease
modifying
therapy.
Depending
on
dosing,
can
be
high
risk
psychological
side
effects
including
hallucinations
physical
harm.
Based
above
information,
do
not
currently
support
use
means
slow
progression.
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration,
Год журнала:
2023,
Номер
24(7-8), С. 572 - 588
Опубликована: Июль 19, 2023
Introduction:
Amyotrophic
lateral
sclerosis
(ALS)
is
a
neurodegenerative
disorder
associated
with
cognitive
and
behavioral
impairments
motor
symptoms.
Magnetic
resonance
imaging
(MRI)
biomarkers
have
been
investigated
as
potential
tools
for
detecting
monitoring
memory-related
impairment
in
ALS.
Our
objective
was
to
examine
the
importance
of
identifying
MRI
ALS,
neuron
disease
(MND),
ALS
frontotemporal
dementia
(FTD)
(ALS-FTD)
patients.
Methods:
PubMed
Scopus
databases
were
searched.
Keywords
covering
magnetic
imaging,
MND,
memory
There
total
25
studies
included
our
work
here.
Results:
The
structural
(sMRI)
reported
gray
matter
(GM)
atrophy
regions
processing,
such
hippocampus
parahippocampal
gyrus
(PhG),
diffusion
tensor
(DTI)
showed
white
(WM)
alterations
corticospinal
tract
(CST)
other
tracts
that
are
related
extra-motor
functions,
these
executive
function
functional
(fMRI)
also
demonstrated
an
altered
activation
prefrontal
cortex,
limbic
system,
brain
involved
emotional
processing
Conclusion:
show
promise
uncovering
neural
mechanisms
Nonetheless,
addressing
challenges
sample
sizes,
protocols,
longitudinal
crucial
future
research.
Ultimately,
be
tool
Physiological Reports,
Год журнала:
2024,
Номер
12(1)
Опубликована: Янв. 1, 2024
Abstract
Sarcopenia
is
a
systemic
skeletal
muscle
disease
characterized
by
decline
in
mass
and
function.
Originally
defined
as
an
age‐associated
condition,
sarcopenia
presently
also
encompasses
muscular
atrophy
due
to
various
pathological
factors,
such
intensive
care
unit‐acquired
weakness,
inactivity,
malnutrition.
The
exact
pathogenesis
of
still
unknown;
herein,
we
review
the
roles
neuromuscular
junction
mitochondria
this
condition.
caused
complex
interdependent
pathophysiological
mechanisms,
including
aging,
impairment,
mitochondrial
dysfunction,
insulin
resistance,
lipotoxicity,
endocrine
oxidative
stress,
inflammation.
Among
these,
instability
dysfunction
are
particularly
significant.
Dysfunction
can
lead
weakness
or
paralysis.
Mitochondria,
which
plentiful
neurons
fibers,
play
important
role
transmission.
Therefore,
impairments
both
may
be
one
key
mechanisms
leading
sarcopenia.
Moreover,
article
explores
structural
functional
alterations
sarcopenia,
suggesting
that
deeper
understanding
these
changes
could
provide
valuable
insights
for
prevention
treatment
iScience,
Год журнала:
2024,
Номер
27(3), С. 109166 - 109166
Опубликована: Фев. 9, 2024
Cytoplasmic
mislocalization
and
aggregation
of
the
RNA-binding
protein
TDP-43
is
a
pathological
hallmark
motor
neuron
(MN)
disease
amyotrophic
lateral
sclerosis
(ALS).
Furthermore,
while
mutations
in
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(19), С. 14647 - 14647
Опубликована: Сен. 27, 2023
Cognitive
dysfunction
is
an
important
non-motor
symptom
in
amyotrophic
lateral
sclerosis
(ALS)
that
has
a
negative
impact
on
survival
and
caregiver
burden.
It
shows
wide
spectrum
ranging
from
subjective
cognitive
decline
to
frontotemporal
dementia
(FTD)
covers
various
domains,
mainly
executive/attention,
language
verbal
memory
deficits.
The
frequency
of
impairment
across
the
different
ALS
phenotypes
ranges
30%
75%,
with
up
45%
fulfilling
criteria
FTD.
Significant
genetic,
clinical,
pathological
heterogeneity
reflects
deficits
domains.
Modern
neuroimaging
studies
revealed
degeneration
widespread
involvement
limbic
white
matter
systems,
hypometabolism
relevant
areas.
Morphological
substrates
are
hippocampal
atrophy
synaptic
loss,
associated
TDP-43
other
co-pathologies,
including
tau
deposition.
Widespread
functional
disruptions
motor
extramotor
networks,
as
well
frontoparietal,
frontostriatal
connectivities,
markers
for
ALS.
reserve
may
moderate
effect
brain
damage
but
not
protective
against
decline.
natural
history
its
relationship
FTD
fully
understood,
although
there
overlap
between
variants
ALS-related
syndromes,
suggesting
differential
vulnerability
networks.
An
assessment
risks
or
early
detection
connectivity
signatures
before
structural
changes
be
helpful
investigating
pathophysiological
mechanisms
ALS,
which
might
even
serve
novel
targets
effective
disease-modifying
therapies.
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration,
Год журнала:
2024,
Номер
25(5-6), С. 486 - 495
Опубликована: Апрель 9, 2024
Objective
Amyotrophic
Lateral
Sclerosis
(ALS)
is
a
heterogeneous
neurodegenerative
condition
featuring
variable
degrees
of
motor
and
cognitive
impairment.
We
assessed
the
impact
specific,
empirically
derived
occupational
skills
requirements
on
functioning
in
ALS.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(14), С. 7503 - 7503
Опубликована: Июль 9, 2024
Sarcopenia
refers
to
the
progressive
loss
and
atrophy
of
skeletal
muscle
function,
often
associated
with
aging
or
secondary
conditions
involving
systemic
inflammation,
oxidative
stress,
mitochondrial
dysfunction.
Recent
evidence
indicates
that
function
is
not
only
influenced
by
physical,
environmental,
genetic
factors
but
also
significantly
impacted
nutritional
deficiencies.
Natural
compounds
antioxidant
properties,
such
as
resveratrol
vitamin
D,
have
shown
promise
in
preventing
dysfunction
cells.
These
antioxidants
can
slow
down
regulating
functions
neuromuscular
junctions.
This
review
provides
an
overview
molecular
mechanisms
leading
summarizes
recent
advances
using
D
supplementation
for
its
prevention
treatment.
Understanding
these
implementing
combined
interventions
optimize
treatment
outcomes,
ensure
recovery,
improve
quality
life
patients.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(19), С. 14927 - 14927
Опубликована: Окт. 5, 2023
Amyotrophic
lateral
sclerosis
(ALS)
is
a
neurodegenerative
disease,
characterized
in
its
typical
presentation
by
combination
of
lower
and
upper
motor
neuron
symptoms,
with
progressive
course
fatal
outcome.
Due
to
increased
recognition
the
non-motor
it
currently
considered
multisystem
disorder
great
heterogeneity,
regarding
genetical,
clinical,
neuropathological
features.
Often
underestimated,
autonomic
signs
symptoms
have
been
described
patients
ALS,
various
method
analyses
used
assess
nervous
system
involvement.
The
aim
this
paper
offer
narrative
literature
review
on
disturbances
based
scarce
data
available
date.
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration,
Год журнала:
2024,
Номер
25(5-6), С. 648 - 652
Опубликована: Апрель 26, 2024
Spurred
by
patient
interest,
ALSUntangled
herein
examines
the
potential
of
Portable
Neuromodulation
Stimulator
(PoNS™)
in
treating
amyotrophic
lateral
sclerosis
(ALS).
The
PoNS™
device,
FDA-approved
for
treatment
gait
deficits
adult
patients
with
multiple
sclerosis,
utilizes
translingual
neurostimulation
to
stimulate
trigeminal
and
facial
nerves
via
tongue,
aiming
induce
neuroplastic
changes.
While
there
are
early,
promising
data
PoNS
improve
balance
stroke,
traumatic
brain
injury,
no
pre-clinical
or
clinical
studies
have
been
performed
ALS.
Although
reasonably
safe,
high
costs
prescription
requirements
will
limit
accessibility.
At
this
time,
due
lack
ALS-relevant
data,
we
cannot
endorse
use
as
an
ALS
treatment.
